قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Israeli Innovative Cancer Treatment Receives FDA Seal of Approval – HEALTH & SCIENCE

Israeli Innovative Cancer Treatment Receives FDA Seal of Approval – HEALTH & SCIENCE



  Israeli Innovative Cancer Treatment Seals FDA Approval

Cancer (Illustrative).
(photo credit: PIXABAY)

The world's first cancer cell proliferation drug, created by Israeli physician Dr. Sharon Shaham, has just received FDA approval, beginning the leukemia awareness month. XPOVIO was developed by Karyopharm Therapeutics, a leading cancer treatment company.

Dr. Sharon Shacham, who co-founded Karyopharm Therapeutics, wrote in a press release: "We believe our activity at Karyopharm is an important stage in the war on cancer."

The FDA first approved the drug for sale in July after 1

0 years of development. Cariopharm wrote in a press release that within six days of FDA approval, cancer patients in the United States began receiving XPOVIO and approximately 40% of patients saw their tumors shrink in size. Karyopharm also reports that patients' life expectancy is increasing 3-5 times thanks to the new treatment.

XPOVIO is used mainly to treat myeloma leukemia, which is the second most common type of leukemia and affects 400-500 people in Israel annually According to a press release from Karyopharm Therapeutics

While XPOVIO is used mainly to treat leukemia from myeloma, it has greater implications for the future of cancer treatment and may be the response of patients with other cancers. In a press release, Cariopharm says the treatment is "a shift to advanced clinical trials with various types of cancer patients, including myeloma, lymphoma, sarcoma, uterine cancer and brain cancer."

The greatest challenge in the fight against cancer is understanding why the body allows cancer cells to grow in the first place, but Cariopharm attributes its success to developing a treatment that focuses on a protein that plays a key role in cancer growth, which is how XPOVIO fights the disease.

Anat Haas Mizrahi, general manager of Karyopharm, writes that "Most of the clinical trials are open to patients in Israel. Naturally, we will continue to work to obtain approval for the sale and sale of OPDIVO in Israel."

`;
document.getElementById ("linkPremium"). innerHTML = cont;
(function (v, i) {
});



Source link